Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE study of AR101 for oral immunotherapy in peanut allergy
2015-004257-41Phase 3Completed
- Sponsor
- Aimmune Therapeutics
- Start
- Nov 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing AR101 oral immunotherapy with Placebo (2 arms). Started Nov 2015; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2015-004257-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004257-41.